Evidence map›Paper›PMID 24592324›Full record

ReviewF1000prime reports2014

Recent advances in hypertrophic cardiomyopathy.

Teerapat Yingchoncharoen, Wh Wilson Tang

Abstract readReview
In one paragraph

Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cold Spring Harbor molecular case studies · 2017
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Teerapat YingchoncharoenHeart and Vascular Institute, Cleveland Clinic 9500 Euclid Avenue, Cleveland, OH 44195 USA.
Wh Wilson TangHeart and Vascular Institute, Cleveland Clinic 9500 Euclid Avenue, Cleveland, OH 44195 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several advances in molecular genetics and cardiac imaging of patients with hypertrophic cardiomyopathy (HCM) have been developed in recent years. The commercially available genetic testing is currently used (a) to identify affected relatives in families known to have HCM and (b) to differentiate HCM from metabolic storage disorders and other HCM phenocopies. Cardiovascular magnetic resonance has emerged as a useful tool to assess the magnitude and distribution of hypertrophy or mitral valve apparatus anatomy, which may have an impact on decision making regarding invasive management of HCM.

Identifiers

PMID24592324
PMCPMC3914503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.